Takeda gives EVP the reins at new subsidiary Nycomed; Indonesia's Kalbe taps deal-scouting team;

@FiercePharma:  AstraZeneca settles Seroquel patent suit, giving Handa license to launch copycat drug in 2016 $AZN #pharma. Report | Follow @FiercePharma

> Takeda Pharmaceutical has wrapped up its €9.6 billion buyout of the Swiss drugmaker Nycomed and named its own EVP, Dr. Frank Morich, as CEO of the new wholly owned subsidiary. Report

> Indonesia's Kalbe Farma, the largest drugmaker in Southeast Asia, has formed an M&A scouting team to look for deals in the region, some in consumer healthcare. News

> Pfizer ($PFE) is teaming up with a pharmacy standards group on an educational campaign to warn patients about counterfeit prescription drugs. Story

> A U.S. District Judge has sent an OxyContin liability suit back to Kentucky, where it was originally filed by the state attorney general; Purdue Pharma had originally petitioned for the jurisdictional move. Article

> Sanofi ($SNY) sold $1 billion of senior unsecured notes maturing 2014 at a yield of 1.242%. Item

> Pfizer spent $3.6 million on lobbying the federal government during the second quarter focusing on patent issues, drug shortages and healthcare reform implementation. Report

> Merck ($MRK) spent $1.1 million on lobbying during the second quarter--a 19% increase from the same period last year--as it focused on healthcare reform implementation and taxes. More

> Bristol-Myers Squibb ($BMY) spent $560,000 during the second quarter on lobbying the federal government, down from $980,000 year-over-year. Piece

Biotech News

@FierceBiotech: Most read on FierceBiotech this week: FDA readies release of long-awaited rules on biosimilars. Story | Follow @FierceBiotech

 @ JohnCFierce: I think next year I will do two Fierce 15s, one for Europe, one for the U.S. Follow @JohnCFierce

@RyanMFierce: Geron has new CEO to lead through first-ever US trial of embryonic stem cell therapy. News | Follow @RyanMFierce

 @MaureenFierce: Google AdWords ban keeps drug savings from U.S. poor. Article | Follow @MaureenFierce

> Cubist green lights Ph3 program against lethal diarrhea. Item

> J&J and Bayer's Xarelto wins where Pfizer drug lost. Article

> AstraZeneca flunks Ph2 lung cancer trial with drug from Array BioPharma. Report

And Finally... Twitter study maps users' mood cycles. Report

Suggested Articles

Bristol-Myers already has one Opdivo combo approved in kidney cancer, but it’s going for another—and new trial data could be just the ticket.

Trodelvy's bladder cancer data look weaker compared with what Seattle Genetics' rival drug Padcev achieved in its own trial.

Merck’s Keytruda is battling Bristol Myers' Opdivo in adjuvant melanoma, and it just racked up trial results that will help it even the playing field.